Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
Body unavailable. Use the original source.
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.